Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

Launched by ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH · Nov 3, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called [18F]PSMA-1007 PET/CT to see how well it can help doctors diagnose newly diagnosed high-risk or very-high-risk prostate cancer. The goal is to determine if this imaging method can provide more accurate information about the cancer, which may help in planning the best treatment options for patients. The trial is currently looking for male participants aged 18 and older who have recently been diagnosed with prostate cancer and are considering surgery as their treatment.

To be eligible for this study, participants must have a confirmed diagnosis of localized prostate cancer that falls into a high-risk category, meaning certain factors indicate a more aggressive form of the disease. They should have had previous imaging tests, like a CT or MRI, to check for any spread of cancer. It’s important to note that participants cannot have received any prior treatment for their cancer or have certain medical conditions that would prevent them from undergoing the PET/CT scans. Those who join the trial can expect to undergo the new imaging procedure, and their participation will help researchers gather important information that could improve prostate cancer diagnosis and treatment in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. The patient (male) is aged 18 years or above.
• • 2. The patient is able to understand the information presented to him concerning the nature, scope, and consequences of the trial as set out in the information provided to the patient AND has provided written informed consent to participate.
• • 3. The patient has newly diagnosed, biopsy-proven, clinically localized prostate adenocarcinoma, and curative prostatectomy with extended pelvic lymph node dissection is his preferred course of treatment.
• 4. The patient has at least high-risk disease as defined by the NCCN guidelines (version 1.2023). That is, the presence of any one or more of the following:
• • Overall ISUP grade group 4 or 5,
• • Clinical category T3a or greater,
• • Serum PSA level greater than 20 ng/ml.
• • 5. The patient has undergone conventional imaging (CT or MRI, and bone scan if clinically indicated) to detect the presence of pelvic nodal involvement and bone or visceral metastases within 60 days of the planned PET-CT procedure.
• Exclusion Criteria:
• • 1. Patients for whom radical prostatectomy is not clinically appropriate or the patient is otherwise unlikely to undergo radical prostatectomy with extensive pelvic lymph node dissection.
• • 2. The patient has received any therapy - be it radiation, surgical or drug therapy - for his prostate cancer.
• • 3. The patient has any contraindication(s) for and/or known hypersensitivity to any constituent(s) of \[18F\]PSMA-1007.
• • 4. The patient is not able to have PET-CT scans (for example, because of weight, claustrophobia, or inability to lie still for the duration of the scan).
• • 5. The patient is closely affiliated to the investigation site; e.g. is a first-degree relative of the investigator.
• • 6. At the time of screening, the patient is receiving any other investigational agent(s), or he has received any such agent(s) within the previous 30 days, or he is scheduled to receive any such agent(s) in the period up to the planned date for the last study visit.
• • 7. The patient has previously been enrolled in this trial.
• • 8. The patient has previously undergone PET imaging with any PSMA-avid product.
• • 9. The patient has histological evidence of small-cell carcinoma of the prostate.
• • 10. The patient is clinically unstable or requires emergency treatment.
• • 11. The patient has any mental condition rendering him incapable of understanding the nature, scope, and consequences of the trial as set out in the information given to the patient.